Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03122106 · ClinicalTrials.gov registry record · Phase 1
Neoantigen DNA Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy
A Phase 1 study, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT03122106 is a Phase 1 study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 15 participants.
The verdict
NCT03122106, a Phase 1 study, was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
This is a phase 1 open-label study to evaluate the safety and immunogenicity of a neoantigen DNA vaccine strategy in pancreatic cancer patients following surgical resection and adjuvant chemotherapy. The neoantigen DNA vaccines will incorporate prioritized neoantigens and personalized mesothelin epitopes and will be administered with an electroporation device. The hypothesis of this study is that neoantigen DNA vaccines will be safe and capable of generating measurable neoantigen-specific CD4 and CD8 T cell responses.
Interventions
- BIOLOGICAL Personalized neoantigen DNA vaccine
- PROCEDURE Peripheral blood draws
- DEVICE TDS-IM Electrode Array System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2018-01-05 |
| Est. Completion | 2022-08-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03122106
The ClinicalTrials.gov registry entry for NCT03122106 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Personalized neoantigen DNA vaccine is the first listed.
NCT03122106 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03122106 about?
NCT03122106 is a clinical study titled "Neoantigen DNA Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy". This is a phase 1 open-label study to evaluate the safety and immunogenicity of a neoantigen DNA vaccine strategy in pancreatic cancer patients following surgical resection and adjuvant chemotherapy. The neoantigen DNA vaccines will incorporate prioritized neoantigens and personalized mesothelin epi...
What is the current status of trial NCT03122106?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2018-01-05. Estimated completion is 2022-08-13.
What interventions are being tested in trial NCT03122106?
The interventions under investigation include: Personalized neoantigen DNA vaccine (BIOLOGICAL), Peripheral blood draws (PROCEDURE), TDS-IM Electrode Array System (DEVICE).
Who is sponsoring clinical trial NCT03122106?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.